Monday, December 11, 2023

AI Corner: AI Reports on Digital Pathology Conference That Hasn't Happened Yet

Next March, I'm excited to be chairing a session and appearing on a panel at the annual TRI-CON conference, which will be held in San Diego March 26-28, 2024.  Find it here:

I noticed one of the tracks is, "ARTIFICIAL INTELLIGENCE IN DIAGNOSTICS."  I fed the agenda and presentation summaries into Chat GPT4 and asked for a journalist-style discussion of the conference, as if the conference had already occured.


Artificial Intelligence in Precision Oncology: 
A Transformative Leap in Cancer Care

By [Name], Health Technology Journalist

The recent conference on "Artificial Intelligence in Precision Oncology" has concluded, leaving attendees, including myself, buzzing with excitement about the potential AI holds in transforming cancer care. The event showcased groundbreaking innovations, thoughtful discussions, and a shared vision for a future where AI and healthcare converge to offer unprecedented precision in oncology.

Innovations at the Forefront

Douglas Flora, MD, set the tone with an insightful opening, emphasizing the need for AI in overcoming the challenges faced in oncology. His vision was echoed in Ben Freeberg's presentation, which focused on using AI to innovate and commercialize in oncology. Freeberg highlighted the unsustainable rise in cancer care costs and how AI could be a game-changer in this landscape.

One of the most compelling talks was by Eric Stahlberg, PhD, who delved into the world of digital twins and virtual models. His presentation painted a future where diagnostics, virtual models, and AI algorithms merge, offering new avenues for optimal treatment in precision medicine.

Paving the Way for Integration

The next day kicked off with Stephen T. C. Wong, PhD, who brought to light the challenges of integrating AI into the complex healthcare ecosystem. This was further explored by Sonya Makhni, MD, who emphasized the necessity of a novel approach to solution evaluation and bias assessment in AI models.

An intriguing approach was presented by Yuan Luo, PhD, who talked about using deep reinforcement learning for cost-effective medical diagnosis. Luo's work in applying reinforcement learning to optimize lab test panel selection could lead to significant cost reductions in clinical tasks.

The conference also shined a spotlight on cognitive automation, with Wong demonstrating how AI could surpass clinicians' performance in tasks like breast cancer overdiagnosis and stroke diagnosis in emergency settings.

Future Directions and Regulatory Considerations

The final day, chaired by Jithesh Veetil, PhD, focused on digital pathology. Veetil's presentation on the role of public-private partnerships highlighted how collaboration could fast-track the adoption of AI in healthcare.

The panel discussion on digital pathology and AI, moderated by Veetil, was particularly enlightening. It brought industry and regulatory leaders together to discuss the progress and hurdles in implementing digital pathology and AI/machine learning. The session underscored the importance of recent regulatory and legislative developments in shaping the future of diagnostics.

Final Thoughts

This conference was not just about the technicalities of AI in oncology but also about envisioning a future where cancer treatment is more personalized, cost-effective, and efficient. It's a future where AI doesn't replace clinicians but works alongside them to enhance precision in cancer care. The enthusiastic participation of leaders in the field and the innovative ideas presented make it clear that this is not a distant dream but an imminent reality. As a health technology journalist, I am excited to see how these advancements unfold in the coming years, bringing hope and improved care to cancer patients worldwide.


Here is an "article" written by Claude.AI.

Artificial Intelligence -
Poised to Revolutionize Cancer Care

I attended the lively AI in Precision Oncology conference this week, which showcased some of the most promising innovations in leveraging AI to improve cancer diagnosis, treatment, and outcomes. As cancer rates and costs continue rising at an alarming rate, there is growing urgency around finding new solutions. Based on the enthusiasm and optimism of presenters and attendees, AI-enabled technologies seem poised to drive a sea change in oncology care.

Several presenters offered compelling examples of how AI tools can support clinicians, reduce costs, and improve patient outcomes all through better use of data. Eric Stahlberg’s presentation on “digital twins” particularly piqued my interest. These virtual computer models of patients, built by aggregating their clinical, molecular, and imaging data, can enable researchers to simulate personalized treatments and predict outcomes. This has enormous potential to get patients on optimal therapies faster while sparing them from unnecessary or overly toxic treatments.

I was also intrigued by the presentation on using reinforcement learning algorithms to optimize diagnostic testing. By continually evaluating which tests provide the best balance of cost and added diagnostic value for a patient, the AI system learned to diagnose conditions accurately while greatly reducing costs. The ability to curb excessive testing offers hope for alleviating economic strains on patients and health systems.

However, as Sonya Makhni cautioned in her talk on responsible AI deployment, unleashing the power of these innovations requires much more than just developing accurate algorithms. Thoughtfully integrating them into complex clinical workflows poses major challenges that could undermine their success if not adequately addressed. Her proposals around novel frameworks for risk assessment and monitoring offer wise guidance for those striving to implement AI tools.

Collaboration is Key

Of course, the 18 experts on the panel discussions repeatedly drove home that partnerships, collaboration, and open channels between stakeholders across specialties will be instrumental in realizing AI’s potential in oncology. Public-private initiatives like those led by MDIC, intended to align interests and amalgamate precious data resources, represent the kinds of joint efforts that will clear the way for AI adoption.

Concluding Notes

If the enthusiasm I witnessed at this conference is any indication, all signs point to AI rapidly permeating virtually every facet of cancer care in the near future. This technological revolution cannot unfold quickly enough for the patients and providers hungry for better solutions. Judging by the fruitful exchanges and ambitious visions on display at the event, many innovators are already racing to unleash AI’s radiant possibilities. I came away confident that this extrahuman intelligence will soon be saving countless lives.

See a Lewis Black version here.